2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Essential Thrombocythaemia: new trials by email Literature Review of Essential Thrombocythaemia trials Research Report on Essential Thrombocythaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Anagrelide retard, Placebo - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 146 | 2010-12-01 | 2016-05-26 |
| Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Anagrelide, Hydroxyurea - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 2002-09-01 | 2010-10-06 |
Thrombocythemia, Essential (2)
Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Bone Marrow Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Myeloproliferative Disorders (2) · Thrombocytosis (2)
Hydroxyurea (1) · anagrelide (1)
AOP Orphan Pharmaceuticals AG (2)
Austria (2) · Lithuania (2) · Poland (2) · Bulgaria (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Romania (1) · Russia (1) · Singapore (1) · Slovakia (1) · Slovenia (1)